Advertisement

Hämatologische Neoplasien: Klinisch latent — aber behandlungsbedürftig?

  • H. Huber
  • B. Fasching
  • J. Drach
  • J. Thaler
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 96)

Zusammenfassung

Die Mehrzahl der Patienten in Frühstadien hämatologischer Neoplasien mit chronischem Krankheitsverlauf zeigt keine oder nur geringe klinische Erscheinungen [5, 32, 48]. Insbesondere fehlen eine Knochenmarkinsuffizienz (Anämie, Thrombopenie), ausgedehntere Organinfiltrationen (Spleno- oder Hepatomegalie, generalisierte Lymphome) oder andere tumorassoziierte klinische Symptome (mit Leukämien einhergehender Hyperkatabolismus, B-Symptomatik bei malignen Lymphomen, ossäre oder renale Komplikationen bei multiplem Myelom).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Alexanian R, Barlogie B, Fritsche H (1985) Beta2 microglobulin in multiple myeloma. Am J Hematol 20:345.PubMedCrossRefGoogle Scholar
  2. 2.
    Alexanian R, Barlogie B, Gutterman J (1990) Alpha interferon combination therapy for multiple myeloma. V. Hannover Interferon Workshop, Hannover 1990, p 43 (abstract).Google Scholar
  3. 3.
    Barlogie B (1990) Management of multiple myeloma. Blut 60:1.PubMedCrossRefGoogle Scholar
  4. 4.
    Barlogie B, Alexanian R, Dixon D, Smith L, Smallwood L, Delasalle K (1985) Prognostic implications of tumor cell DNA and RNA content in multiple myeloma. Blood 66:338.PubMedGoogle Scholar
  5. 5.
    Barlogie B, Epstein J, Selvanayagam P, Alexanian R (1989) Plasma cell myeloma — new biological insights and advances in therapy. Blood 73:865.PubMedGoogle Scholar
  6. 6.
    Bartl R, Frisch B, Burkhardt R, et al. (1982) Bone marrow histology in myeloma: its importance in diagnosis, prognosis, classification and staging. Br J Haematol 51:361.PubMedCrossRefGoogle Scholar
  7. 7.
    Bataille R, Grenier J, Sany J (1984) Beta-2-microglobulin in myeloma: Optimal use for staging, prognosis, and treatment: A prospective study of 160 patients. Blood 63:468.PubMedGoogle Scholar
  8. 8.
    Bataille R, Jourdan M, Zhang X, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84:2008.PubMedCrossRefGoogle Scholar
  9. 9.
    Bergsagel DE (1990) Interferon: mechanisms of action. V. Hannover Interferon Workshop, Hannover 1990, p 36 (abstract).Google Scholar
  10. 10.
    Bergui L, Schena M, Gaidano G, Riva M, Caligaris-Cappio F (1989) Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 170:613.PubMedCrossRefGoogle Scholar
  11. 11.
    Binet JL, Auquier A, Dighiero G, et al. (1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198.PubMedCrossRefGoogle Scholar
  12. 12.
    Binet JL, Catovsky D, Chastang C, et al. (1989) Prognostic features of early chronic lymphocytic leukaemia. Lancet II:968.Google Scholar
  13. 13.
    Boccadoro M, Gavarotti P, Fossati G, et al. (1984) Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undertermined significance (MGUS), smouldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br J Haematol 58:689.PubMedCrossRefGoogle Scholar
  14. 14.
    Catovsky D, Fooks J, Richards S (1988) Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. Br J Haematol 72:141.CrossRefGoogle Scholar
  15. 15.
    Drach J, Gattringer C, Glassi H, Schwarting R, Stein H, Huber H (1989) Simultaneous flow cytometric analysis of surface markers and nuclear Ki-67 antigen in leukemia and lymphoma. Cytometry 10:743.PubMedCrossRefGoogle Scholar
  16. 16.
    Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842.PubMedCrossRefGoogle Scholar
  17. 17.
    Durie BGM, Grogan TM (1985) CALLA-positive myeloma: an aggressive subtype with poor survival. Blood 66:229.PubMedGoogle Scholar
  18. 18.
    Epstein J, Xiao H, He X (1990) Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med 322:664.PubMedCrossRefGoogle Scholar
  19. 19.
    Foon KA (1989) Biological response modifiers: the new immunotherapy. Cancer Res 49:1621.PubMedGoogle Scholar
  20. 20.
    French Cooperative Group on Chronic Lymphocytic Leukemia (1988) Therapy of chronic lymphocytic leukemia: results from the French cooperative trials. Nouv Rev Fr Hematol 30:443.Google Scholar
  21. 21.
    Gassmann W, Pralle H, Haferlach T, Pandurevic S, Graubner M, Schmitz N, Löffler H (1985) Staging system for multiple myeloma: a comparison. Br J Haematol 59:703.PubMedCrossRefGoogle Scholar
  22. 22.
    Gastl G, Aulitzky W, Tilg H (1987) Dose related effectiveness of alpha-interferon in chronic myelogenous leukemia. Blut 54:251.PubMedCrossRefGoogle Scholar
  23. 23.
    Geisler C, Ralfkiaer E, Hansen M, Hou-Jensen K, Olesen-Larsen S (1986) The bone marrow histological pattern has independent prognostic value in early stage chronic lymphocytic leukaemia. Br J Haematol 62:47.PubMedCrossRefGoogle Scholar
  24. 24.
    Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710.PubMedGoogle Scholar
  25. 25.
    Greipp PR, Kyle RA (1983) Clinical, morphological, and cell kinetic differences among multiple myeloma, monoclonal gammopathy of undetermined significance, and smouldering multiple myeloma. Blood 62:166.PubMedGoogle Scholar
  26. 26.
    Greipp PR, Witzig TE, Gonchoroff NJ (1985) Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1). Am J Haematol 20:289.CrossRefGoogle Scholar
  27. 27.
    Greipp PR, Raymond NM, Kyle RA, O’Fallon WM (1985) Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 65:305.PubMedGoogle Scholar
  28. 28.
    Greipp PR, Katzmann JA, O’Fallon WM, Kyle RA (1988) Value of β2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 72:219.PubMedGoogle Scholar
  29. 29.
    Grever MR, Kopecky KJ, Coltman CA, et al. (1988) Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 30:457.PubMedGoogle Scholar
  30. 30.
    Grogan TM, Durie BGM, Spier CM, Richter L, Vela E (1989) Myelomonocytic antigen positive multiple myeloma. Blood 73:763.PubMedGoogle Scholar
  31. 31.
    Han T, Henderson ES, Emrich LJ, Sandberg AA (1987) Prognostic significance of karyotypic abnormalities in B-cell chronic lymphocytic leukemia: an update. Semin Hematol 24:257.PubMedGoogle Scholar
  32. 32.
    Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB (1990) Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 88:1.PubMedCrossRefGoogle Scholar
  33. 33.
    Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB (1988) Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol 30:461.PubMedGoogle Scholar
  34. 34.
    Kurzrock R, Gutterman JU, Talpaz M (1988) The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl Med 319:990.CrossRefGoogle Scholar
  35. 35.
    Lokhorst HM, Boom SE, Terpstra W, Roholl P, Gerdes J, Bast B (1988) Determination of the growth fraction in monoclonal gammopathy with the monoclonal antibody Ki-67. Br J Haematol 69:477.PubMedCrossRefGoogle Scholar
  36. 36.
    Ludwig H, Gisslinger H, Cohen AM, et al. (1990) VMCP versus VMCP/IFN-alpha induction therapy: a randomized trial in multiple myeloma. V. Hannover Interferon Workshop, Hannover 1990, p 45 (abstract).Google Scholar
  37. 37.
    Mandelli F, Tribalto M, Avvisati G, et al. (1988) Recombinant interferon alpha-2b (Intron A) as post-induction therapy for responding multiple myeloma patients. M84 protocol. Cancer Treat Rev 15[Suppl A]:43.CrossRefGoogle Scholar
  38. 38.
    Mellstedt H (1990) MP versus MP/ IFN-alpha induction therapy: a randomized trial in multiple myeloma. V. Hannover Interferon Workshop, Hannover 1990, p 44 (abstract).Google Scholar
  39. 39.
    Mellstedt H, Aahre A, Cantell K, Johansson B, Björkholm M, Holm G, Strander H (1979) Interferon therapy in myelomatosis. Lancet II:697.Google Scholar
  40. 40.
    Meuro A, Havanessian AG (1988) Alpha-interferon inhibits the expression of heavy chain μ messenger RNA in Daudi cells. EMBO J 7:1689.Google Scholar
  41. 41.
    Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C (1986) Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 62:567.PubMedCrossRefGoogle Scholar
  42. 42.
    Niederle N, Kloke O, Doberauer C, Becher R, Beelen DW, Schmidt CG (1986) Alpha2-Interferon: erste Behandlungsergebnisse bei der chronischen myeloischen Leukämie. Dtsch Med Wochenschr 20:767.CrossRefGoogle Scholar
  43. 43.
    Nowell PC (1989) Chromosomal and molecular clues to tumor progression. Semin Oncol 16:116.PubMedGoogle Scholar
  44. 44.
    Oken MM, Kyle RA, Greipp PR, Kay NE, Tsiatis A, O’Connell MJ (1988) Alternating cycles of VBMCP with interferon (rIFN-alpha 2) in the treatment of multiple myeloma. Proc Am Soc Clin Oncol 7:868A.Google Scholar
  45. 45.
    Phillipps EA, Kempin S, Passe S, Mike V, Clarkson B (1977) Prognostic factors in chronic lymphocytic leukemia and their implications for therapy. Clin Haematol 6:203.Google Scholar
  46. 46.
    Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-chlorodoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 71:1069.Google Scholar
  47. 47.
    Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46:219.PubMedGoogle Scholar
  48. 48.
    Rozman C, Montserrat E (1989) Chronic lymphocytic leukaemia: when and how to treat. Blut 59:467.PubMedCrossRefGoogle Scholar
  49. 49.
    Rozman C, Montserrat E, Rodriguez-Fernandez JM, et al. (1984) Bone marrow histologic pattern — the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood 64:642.PubMedGoogle Scholar
  50. 50.
    Rozman C, Montserrat E, Vinolas N, Urbano-Ispizua A, Ribera JM, Gallart T, Compernolle C (1988) Recombinant alpha2-interferon in the treatment of B chronic lymphocytic leukemia in early stages. Blood 71:1295.PubMedGoogle Scholar
  51. 51.
    Samid D, Chang E, Friedman RM (1984) Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun 119:21.PubMedCrossRefGoogle Scholar
  52. 52.
    Samid D, Flessate DM, Friedman RM (1987) Interferon induced revertants of rastransformed cells: resistance to transformation by specific oncogenes and retransformation by 5-azacytidine. Mol Cell Biol 7:2196.PubMedGoogle Scholar
  53. 53.
    Sporn JR, McIntyre OR (1986) Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. Semin Oncol 13:318.PubMedGoogle Scholar
  54. 54.
    Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J (1987) Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69:1280.PubMedGoogle Scholar
  55. 55.
    Tanaka H, Tanabe O, Iwato K (1989) Sensitive inhibitory effect of interferon-alpha on Mprotein secretion of human myeloma cells. Blood 74:1718.PubMedGoogle Scholar
  56. 56.
    Thaler J, Kühr T, Gastl G, et al. (1990) Phase II-trial for treatment of chronic myeloid leukemia with alpha-interferon-2c. Blut (abstract, in press).Google Scholar
  57. 57.
    Tsuchiya H, Epstein J, Selvanayagam P, Dedman JR, Gallick G, Alexanian R, Barlogie B (1988) Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood 72:796.PubMedGoogle Scholar
  58. 58.
    Werter M, Witte R de, Janssen J, Pauw B de, Haanen C (1988) Recombinant human interferon-alpha induced cytoreduction in chronic myelogenoes leukemia. Blut 56:209.PubMedCrossRefGoogle Scholar
  59. 59.
    Woodruff RK, Wadsworth J, Malpas JS, Tobias JS (1979) Clinical staging in multiple myeloma. Br J Haematol 42:199.PubMedCrossRefGoogle Scholar
  60. 60.
    Ziegler-Heitbrock HWL, Schlag R, Flieger D, Thiel E (1989) Favorable response of early stage B CLL patients to treatment with IFN-alpha2. Blood 73:1426.PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin Heidelberg 1990

Authors and Affiliations

  • H. Huber
    • 1
  • B. Fasching
    • 1
  • J. Drach
    • 1
  • J. Thaler
    • 1
  1. 1.Abteilung für Hämatologie und Onkologie, Klinik für Innere MedizinUniversität InnsbruckDeutschland

Personalised recommendations